Research
Research and Education are key interests of Professor Declan Murphy. In the past ten years, he has published many hundreds of manuscripts in peer-reviewed journals, and has delivered hundreds of invited lectures around the world. He has been Chief Investigator on competitive grants in excess of $20m dollars in the past ten years alone, including many clinical and basic scientific studies involving prostate cancer. He has a h-index of 65, meaning that his publications are highly cited. Declan’s research work is predominantly based at Peter MacCallum Cancer Centre, in collaboration with Epworth Healthcare, Cancer Specialists, and the University of Melbourne. He also has ongoing collaborations with other universities, National and International Collaborators, and sits on the National Research Advisory Board of the Prostate Cancer Foundation of Australia.
Current areas of research interest include PSMA PET/CT in diagnosing prostate cancer, 177Lutetium-PSMA theranostic therapy, MRI scanning, robotic surgery, nerve-sparing surgery, and active surveillance.
Declan is also very active in academic publishing with many senior Editorial roles and peer-review activities. He is Associate Editor of European Urology, the world’s highest ranked urology journal, and has served on the Editorial Boards of the British Journal of Urology International, Nature Reviews Urology, the Asian Journal of Urology, Current Opinion in Urology, and Trends in Urology & Men’s Health. He is a regular reviewer for The Journal of Urology, European Urology Focus. European Urology Oncology, Urologic Oncology, Journal of Clinical Oncology, Journal of Endourology, Journal of Sexual Medicine, Cancer, ANZ Journal of Surgery, Journal of Robotic Surgery and many others.
In 2020 and again in 2021, Declan was named by The Australian as Australia’s top researcher in Urology & Nephrology. This was based on his publications and citations in the world’s top 20 journals over the past five years
Research Highlights | 2020
Professor Declan Murphy and colleagues published the outcomes of the proPSMA study in the prestigious Lancet journal in 2020. This practice-changing study establishes the superiority of PSMA PET/CT for staging men with prostate cancer.
Investigator on current clinical trials
A study of the dosimetry, safety and potential benefit of Lu-PSMA radionuclide therapy prior to radical prostatectomy in men with high-risk localised prostate cancer
A prospective multi-centre cross-sectional study of the additive diagnostic value of PSMA PET/CT to mpMRI for men being investigated for prostate cancer
A randomised controlled trial of Lu-PSMA combined with standard of care (SOC), compared with SOC, in men with high-volume metastatic prostate cancer.
An international registry of men with advanced prostate cancer. IRONMAN collects information about type of prostate cancer, treatment and side effects.
A randomised study of an online decision aid. This is aimed at men recently diagnosed with low-risk prostate cancer who are suitable for active surveillance.
A multi-centre phase 3 study to evaluate diagnostic performance of 89Zirconium-labelled girentuximab to detect clear cell renal cell carcinoma using PET/CT
More about Declan’s academic career
Research Gate
Google Scholar
Full CV
Research at Peter Mac
Professor Murphy and his colleagues Professor Nathan Lawrentschuk and Dr Marlon Perera lead a very productive research team based at Peter MacCallum Cancer Centre. We have close collaborations with the EJ Whitten Prostate Cancer Research Centre at Epworth Healthcare, and with other research sites across Australia and internationally.
Our team meet weekly in person at Peter Mac with external members dialling in by Zoom.
